Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective,Multi-center,Cohort Trial: the Efficacy and Safety of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus(HBV)

NCT04065230 is registered in ClinicalTrials.gov with Southeast University, China as lead sponsor.

NCT NCT04065230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04065230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective,Multi-center,Cohort Trial: the Efficacy and Safety of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus(HBV)
Lead sponsor
Southeast University, China
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2019
Completion date
August 31, 2021
Enrollment
330 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b virus, mother to child transmission